Alternatives to Deep Science Ventures

A deep tech ecosystem providing lab space, expert training, and venture capital for startups.

Developing and industrializing cellulose-based superabsorbent materials as a fossil-free and biodegradable alternative.

Enzyme-based technology to break down alcohol in the stomach.

Developing high-performance, compostable foams from bacterial cellulose to replace fossil-based plastics.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing circular biomass technology.

Cultivating wood directly into its final shape, 10,000x faster than forestry.

Enabling sustainable and scalable manufacturing of complex, high-value biomolecules through enzymatic biomanufacturing.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Global early-stage venture capital firm that builds and invests in the next generation of founders and technology.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Developing next-generation nanozyme catalysts to enable a more sustainable and efficient chemical production industry.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Clinical-stage biotechnology company developing autologous neuron replacement medicines for neurodegenerative disorders.

Developing novel therapeutics to restore gut lymphatic function.

A venture capital firm focused on deeptech investments.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing and commercializing CNS disease treatments.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

Accelerating patient access to evidence-based innovation in mental health.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

Climate tech venture capital firm investing in technologies that reshape cities for sustainability.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

A venture capital firm that operates multiple accelerators and invests in startups globally.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Developing highly targeted, small molecule medicines.

Pioneering vision restoration therapies for severe retinal degenerations.

Turning CO2 into cellulose for textiles using an innovative, carbon-negative enzymatic process.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing next-generation mRNA medicines.

Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity.

A pharmaceutical company focused on developing long-acting injectable medicines.

AI-powered antibody discovery platform.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Clinical-stage biotech company targeting RNA modifications for novel cancer therapies.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Pioneering sustainable oils and fats through fermentation.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.